Osimertinib Mesylate

FDA label information for this drug is available at DailyMed.

Use in Cancer

Osimertinib mesylate is approved to treat:

• Non-small cell lung cancer that has an abnormal EGFR gene. It is used in adults:
  • After surgery to remove the cancer.
  • As the first treatment for cancer that has spread to other parts of the body.
  • For cancer that has spread to other parts of the body and got worse during or after treatment with another EGFR tyrosine kinase inhibitor.
  • With pemetrexed disodium and platinum chemotherapy as the first treatment for cancer that has spread to other parts of the body.

Osimertinib mesylate is also being studied in the treatment of other types of cancer.

More About Osimertinib Mesylate

Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

More About Osimertinib Mesylate – A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism

Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Osimertinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.